Table 2.

Expressions of HER-2, p-HER-2, SOCS3, STAT3 and p-STAT3 with clinicopathological features of ovarian cancer.

		HER2			p-HER2			SOCS3			STAT3			p-STAT3
clinicopathological features	Case	positive	negative	P	positive	negative	P	positive	negative	P	positive	negative	P	positive	negative	P
Age (years)
≤ 50	51	15	36	0.885	17	34	0.434	20	31	0.448	32	19	0.927	27	24	1.000
> 50	85	26	59		22	63		39	46		54	31		45	40
Pathological type
Serous carcinoma	72	21	51	0.497	21	51	0.829	30	42	0.584	47	25	0.183	38	34	0.826
Mucinous carcinoma	36	14	22		14	22		15	21		18	18		21	15
Endometrioid carcinoma	15	3	12		3	12		9	6		12	3		7	8
Clear-cell carcinoma	13	3	10		3	10		5	8		9	4		6	7
Histological grade
High-middle differentiation	52	13	39	0.303	13	39	0.846	28	24	0.053	27	25	0.031	28	24	0.868
Poor differentiation	84	28	56		28	56		31	53		59	25		44	40
Clinical stage
Early stage	56	7	49	< 0.001	7	49	0.002	33	23	0.002	33	23	0.384	20	36	0.001
Terminal stage	80	34	46		34	46		26	54		53	27		52	28
Lymph node metastasis
With	59	23	36	0.049	23	36	< 0.001	18	41	0.008	46	13	0.002	40	19	0.002
Without	77	18	59		18	59		41	36		40	37		32	45

Notes: HER-2, human epidermal growth factor receptor 2; p-HER2, phosphorylated HER2; SOCS3, suppressors of cytokine signaling 3; STAT3, signal transducer and activator of transcription 3; p-STAT3, phosphorylated STAT3.